Literature DB >> 22399602

Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells.

Young-Ki Park1, Dong-Jun Shin, Duck Cho, Sang-Ki Kim, Je-Jung Lee, Myung-Geun Shin, Dong-Wook Ryang, Ji-Shin Lee, Min-Ho Park, Jung Han Yoon, Young Jong Jegal.   

Abstract

BACKGROUND/AIM: Interleukin-21(IL-21) stimulates cytotoxicity and interferon-γ (IFN-γ) production in natural killer (NK) cells. However, little has been reported on the stimulatory effect of IL-21 on ex vivo expanded NK cells. In this study, we examined the cytotoxicity and IFN-γ production of ex vivo expanded, IL-21-stimulated NK cells against trastuzumab-coated breast cancer cells.
MATERIALS AND METHODS: To expand NK cells, peripheral blood mononuclear cells (PBMCs) were isolated and co-cultured with irradiated K562-mb15-41BBL cells in the presence of IL-2 and IL-15 for 3 weeks. After a 4-day stimulation with IL-21, NK cell cytotoxicity and IFN-γ production were measured.
RESULTS: NK cells were expanded up to median of 911-fold and represented approximately 94.93% of expanded cells after 21 days. Cytotoxicity of the expanded NK cells against the MCF-7, SKBR3, and T47D cell lines was significantly increased following 4-day stimulation with IL-21. However, antibody-dependent cellular cytotoxicity mediated by trastruzumab was significantly increased only in the SKBR3 cell line, which highly expresses the HER2/neu antigen. IL-21 pre-treatment also increased IFN-γ production in the expanded NK cells in response to the trastuzumab-coated breast cancer cells.
CONCLUSION: IL-21 significantly enhances the cytolytic activity and IFN-γ production of ex vivo expanded NK cells in response to trastuzumab-coated breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399602

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).

Authors:  Shuzhen Liang; Mao Lin; Lizhi Niu; Kecheng Xu; Xiaohua Wang; Yingqing Liang; Mingjie Zhang; Duanming Du; Jibing Chen
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

2.  Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

Authors:  Caroline Aspord; Laetitia Tramcourt; Claire Leloup; Jean-Paul Molens; Marie-Therese Leccia; Julie Charles; Joel Plumas
Journal:  J Invest Dermatol       Date:  2014-04-21       Impact factor: 8.551

3.  HLA-DR+ NK cells are mostly characterized by less mature phenotype and high functional activity.

Authors:  Sofya A Erokhina; Maria A Streltsova; Leonid M Kanevskiy; William G Telford; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  Immunol Cell Biol       Date:  2017-12-19       Impact factor: 5.126

4.  Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk.

Authors:  Fay Chinnery; Catherine A King; Tim Elliott; Andrew R Bateman; Edward James
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

Review 5.  "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy.

Authors:  Senthamil R Selvan; John P Dowling
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

6.  Activation of cellular immunity and marked inhibition of liver cancer in a mouse model following gene therapy and tumor expression of GM-SCF, IL-21, and Rae-1.

Authors:  Mingrong Cheng; Kangkang Zhi; Xiaoyan Gao; Bing He; Yingchun Li; Jiang Han; Zhiping Zhang; Yan Wu
Journal:  Mol Cancer       Date:  2013-12-18       Impact factor: 27.401

7.  A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.

Authors:  Juliane Wagner; Viktoria Pfannenstiel; Anja Waldmann; Judith W J Bergs; Boris Brill; Sabine Huenecke; Thomas Klingebiel; Franz Rödel; Christian J Buchholz; Winfried S Wels; Peter Bader; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-06-12       Impact factor: 7.561

8.  Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response.

Authors:  Oana Tudoran; Oana Virtic; Loredana Balacescu; Carmen Lisencu; Bogdan Fetica; Claudia Gherman; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  Onco Targets Ther       Date:  2015-11-18       Impact factor: 4.147

9.  Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3+CD5dimCD21- Cytotoxic Large Granular Lymphocytes.

Authors:  Soo-Hyeon Lee; Dong-Jun Shin; Yoseop Kim; Cheol-Jung Kim; Je-Jung Lee; Mee Sun Yoon; Tung Nguyen Thanh Uong; Dohyeon Yu; Ji-Youn Jung; Duck Cho; Bock-Gie Jung; Sang-Ki Kim; Guk-Hyun Suh
Journal:  Front Immunol       Date:  2018-04-27       Impact factor: 7.561

10.  Cytokine-Modulated Natural Killer Cells Differentially Regulate the Activity of the Hepatitis C Virus.

Authors:  Yoo Jin Cho; Hwan Hee Lee; Hyojeung Kang; Hyosun Cho
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.